KRAS and non-small cell lung carcinoma: STK11/LKB1 genomic alterations are associated with primary resistance to PD-1 axis inhibitors in PD-L1 positive NSCLC with significantly shorter PFS and OS in such patients regardless of PD-L1 and KRAS mutation status.